EW files 8-K — Item 7.01 Regulation FD

What Was Filed

Edwards Lifesciences Corporation (EW), a $48.4B market cap medical devices company, filed an 8-K with the SEC on May 4, 2026, at 16:53:21, disclosing Items 5.02 and 7.01, with Item 7.01 (Regulation FD) listed as the lead disclosure. Item 7.01 covers furnishing of material non-public investor information, while Item 5.02 addresses executive officer departures or appointments. The full filing is available at https://www.sec.gov/Archives/edgar/data/1099800/000109980026000023/ew-20260502.htm.

The Disclosure

The dual disclosure packages two material corporate updates: a Regulation FD clinical data release tied to the company’s Resilia Tissue transcatheter heart valve platform, and a CFO appointment. The Item 7.01 filing aligns with a May 2, 2026, press release announcing ten-year pivotal clinical data demonstrating long-term tissue durability, while Item 5.02 corresponds to a May 4, 2026, Business Wire headline regarding a new CFO appointment. This combined submission delivers both a key clinical milestone and a critical leadership change in a single regulatory filing.

Cross-Reference to Prior Signals

This 8-K follows a wave of insider stock sales by senior EW executives in early April 2026, all disclosed via Form 4 filings. On April 2, 2026, Donald E. Bobo Jr., CVP of Strategy and Corporate Development, sold 22,680 exempt shares and 22,680 sold shares for total proceeds of ~$1.82M. On April 6, Daniel J. Lippis, CVP of TAVR, sold 1,019 exempt shares and 1,019 sold shares for ~$142,906. On April 9, Scott B. Ullem—then serving as EW’s CFO per his April 9 Form4 filing—sold 13,000 exempt shares and 12,999 sold shares for total proceeds of ~$1.04M. Analyst ratings have remained flat since January 2026, with 5 strong buy, 17 buy, and 10 hold ratings, with no sell or strong sell ratings assigned through May 4, 2026. Institutional ownership as of December 31, 2025, stood at 86.3% of float, with 600 institutions increasing positions and 472 reducing positions in the prior quarter.

Unanswered Critical Details

Three key gaps remain in the public filing details: first, the exact terms of the new CFO appointment, including the successor’s name, compensation package, and start date; second, granular clinical endpoints and patient cohort data from the Resilia Tissue ten-year trial, beyond the headline summary; third, any regulatory next steps tied to the Resilia data, such as a planned FDA submission or labeling update.